Bichu et al 19. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investiga- tors. N Engl J Med. 2000;342(3):145–153. 20. Rodby R, Rohde R, Lewis E, et al. The Irbesartan Type II Diabetic Nephropathy Trial. Nephrol Dial Transplant. 2000;15:487–497. 21. Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860. 22. Parving H, Lehnert H, Arner P, et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878. 23. Brenner B, Cooper M, Zeeuw D, et al. RENAAL Study Investigators. Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study. N Engl J Med. 2001;345(12):861–869. 24. De Zeeuw D, Remuzzi G, Parving H, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309–2320. 25. Viberti G, Wheeldon NM, et al. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduc- tion with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672–678. 26. Ruggenenti P, Fassi A, Ilieva A, et al. Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbu- minuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941–1951. 27. Remuzzi G, Macia M, Ruggenenti P, et al. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol. 2006;17(4 Suppl 2):S90–S97. 28. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet. 2008;372(9638):547–553. 29. Barnett AH, Bain SC, Bouter P, et al. Diabetics Exposed to Telmisar- tan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351(19):1952–1961. 30. Schmieder R, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30:1351–1356. 31. Galle J, Schwedhelm E, Pinnetti S, et al. VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisar- tan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant. 2008; 23(10):3174–3183. 32. Makino H, Haneda M, Babazono T, et al. The Telmisartan Renopro- tective Study from Incipient Nephropathy to Overt Nephropathy – Rationale, Study Design, Treatment Plan and Baseline Characteristics of the Incipient to Overt: Angiotensin II Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. J Int Med Res. 2005;33:677–686. 33. Yusuf S, Teo K, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59. 34. Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25(9):1921–1926. 35. Rossing K, Schjoedt KJ, Parving H, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005;68(3):1190–1198. 36. Benson SC, Pershadsingh H, Ho C, et al. Identiﬁcation of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ- modulating activity. Hypertension. 2004;43:993–1002. 37. Wienen W, Hauel N, Van Meel J, et al. Pharmacological characteriza- tion of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol. 1993;110(1):245–252. 38. Wolfgang W, Entzeroth M, Stangier J, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor. Cardiovasc Drug Rev. 2006;18(2):127–154. 39. Kakuta H, Sudoh K, Sasamata M, et al. Telmisartan has the strongest binding afﬁnity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Re. 2005;25(1):41–46. 40. Panchapakesan U, Pollock C, X Chen, et al. PPAR gamma agonists exert antiﬁbrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol. 2005;289:F1153–F1158. 41. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body ﬂuid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005;11(8):861–866. 42. Yang T, Soodvilai S. Renal and vascular mechanisms of thiazoli- dinedione-induced ﬂuid retention. PPAR Research. 2008;943614: doi:10.1155. 43. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes. 2005;54(12):3442–3452. 44. Zhang H, Zhang A, Kohan DE, et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced ﬂuid retention. Proc Natl Acad Sci U S A. 2005;102(26):9406–9411. 45. Rubenstrunk A, Hanf R, Hum D, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta. 2007;1771(8):1065–1081. 46. Zhang F, Lavan B, Gregoire F, et al. Selective modulators of PPAR-γ activity: molecular aspects related to obesity and side-effects. PPAR Res. 2007;32696:doi:10.1155. 47. Zhou X, Ono H, Frohlich E, et al. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics. Am J Nephrol. 2004;24:242–249. 48. Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577–1578. 140 Vascular Health and Risk Management 2009:5